1. Report Overview

1.1 Rheumatoid Arthritis Overview

1.2 Rheumatoid Arthritis Market Segmentation

1.3 Why You Should Read this Report

1.4 How this Report Delivers

1.5 Main Questions Answered by this Report

1.6 Who is this Report for?

1.7 Research and Analysis Methods

1.8 Frequently Asked Questions (FAQ)

1.9 Some Associated Reports

1.10 About Visiongain

2. What is Rheumatoid Arthritis?

2.1 What Causes Rheumatoid Arthritis?

2.2 How Does the Disease Develop?

2.3 How Can It Be Monitored?

2.4 Can RA Be Cured?

2.5 Performance Criteria Used in Clinical Trials

2.5.1 ACR Criteria For Drug Efficacy

2.5.2 HAQ-DI Measures Daily Activities

2.5.3 mSS Assesses Disease on X-Ray

2.5.4 DAS28 For Disease Severity

2.6 How is RA Treated?

2.6.1 Biologic DMARDs Are the Dominant Source of Revenue

2.6.2 Synthetic DMARDs are the Mainstay of Treatment

2.6.3 Others

2.6.3.1 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

2.6.3.2 Corticosteroids for Rapid Anti-Inflammatory Effect

2.6.3.3 Analgesics for Rapid Pain Relief

2.7 Comorbid Conditions Associated with RA

2.8 Prevalence and Incidence Rates of Rheumatoid Arthritis

3. World Drug Market for Rheumatoid Arthritis 2017-2027

3.1 The Global Rheumatoid Arthritis Market, 2016

3.2 The Global RA Drugs Market: Revenue Forecast 2016-2027

3.3 The Global RA Drugs Market Segments: Revenue Forecast 2016-2027

3.4 Non-Biologics for RA

3.4.1 NSAIDs: Revenue Forecast, 2016-2027

3.4.2 Synthetic DMARDs: Revenue Forecast, 2016-2027

3.4.3 Others: Revenue Forecast, 2016-2027

3.5 Biologics for RA: Revenue Forecast 2016-2027

4. Leading Drugs in the RA Market 2017-2027

4.1 The Main Drugs in the RA Market, 2016

4.2 Humira: A Major Source of Revenue for AbbVie

4.2.1 Adalimumab Biosimilars

4.2.2 Humira: Revenue Forecast 2016-2027

4.3 Enbrel: Amgen’s Revenue Protected Until 2028

4.3.1 Etanercept Biosimilars

4.3.2 Enbrel: Revenue Forecast 2016-2027

4.4 Remicade: Facing Significant Competition from Biosimilars

4.4.1 Infliximab Biosimilars

4.4.2 Remicade: Revenue Forecast 2016-2027

4.5 Rituxan: Facing Declining Market Share

4.5.1 Rituximab Biosimilars

4.5.2 Rituxan: Revenue Forecast 2016-2027

4.6 Simponi: Market Share Remaining Stable

4.6.1 Simponi: Revenue Forecast 2016-2027

4.7 Orencia: Additional Indications Being Explored

4.7.1 Abatacept Biosimilars

4.7.2 Orencia: Revenue Forecast 2016-2027

4.8 Actemra: First IL-6R Inhibitor Approved for RA

4.8.1 Tocilizumab Biosimilars

4.8.2 Actemra: Revenue Forecast 2016-2027

4.9 Cimzia: Reliable Source of Income for UCB

4.9.1 Certolizumab Biosimilars

4.9.2 Cimzia: Revenue Forecast 2016-2027

4.10 Celebrex: Facing Generic Competition

4.10.1 Celebrex: Revenue Forecast 2016-2027

4.11 Xeljanz: Good Opportunity for Revenue Growth

4.11.1 Xeljanz: Revenue Forecast 2016-2027

4.12 Arcoxia: Sales Revenue Already Declining

4.12.1 Arcoxia: Revenue Forecast 2016-2027

5. Leading National Markets for Rheumatoid Arthritis 2016-2027

5.1 The Leading National Markets in 2016

5.2 The Leading National Markets: Comparison of Revenues and Market Shares to 2027

5.3 The Leading National Markets: Grouped Revenue Forecasts 2017-2027

5.4 The US: Prosperous Economy and Large Patient Population Enables it to dominate the RA Drugs Market

5.4.1 The US RA Drug Market: Revenue Forecast 2017-2027

5.5 Japan: Remains the Second Largest National Market

5.5.1 The RA Drug Market in Japan: Revenue Forecast 2017-2027

5.6 The EU5 Have 18% Market Share

5.6.1 The RA Drug Market in Germany: Revenue Forecast 2017-2027

5.6.2 The RA Drug Market in France: Revenue Forecast 2017-2027

5.6.3 The RA Drug Market in Italy: Revenue Forecast 2017-2027

5.6.4 The RA Drug Market in Spain: Revenue Forecast 2017-2027

5.6.5 The RA Drug Market in the UK: Revenue Forecast 2016-2026

5.7 China: Expanding Economy with Increasing Market Share

5.7.1 The RA Drug Market in China: Revenue Forecast 2017-2027

5.8 India: Expanding Population Driving Growth

5.8.1 The RA Drug Market in India: Revenue Forecast 2017-2027

5.9 Russia: Expansion Held Back by Troubled Economy

5.9.1 The RA Drug Market in Russia: Revenue Forecast 2017-2027

5.10 Brazil: Focus on Domestic Drug Manufacturing

5.10.1 The RA Drug Market in Brazil: Revenue Forecast 2017-2027

6. Rheumatoid Arthritis R&D Pipeline 2016

6.1 IL-6 Inhibitors Could Rival TNF-Inhibitors

6.1.1 Sarilumab: Already Filed With FDA

6.1.2 Sirukumab: Expected to File in Q3, 2016

6.1.3 Olokizumab: Promising Phase 2 Data

6.1.4 Clazakizumab: Alder Now Collaborating with Vitaeris

6.2 JAK Inhibitors: A Promising Class of Agents

6.2.1 Baricitinib: Potential Competitor to Xeljanz

6.2.2 Peficitinib: Selective JAK-3 Inhibitor From Astellas

6.2.3 ABT-494: Selective JAK-1 Inhibitor From AbbVie

6.2.4 Filgotinib: Following AbbVie’s Withdrawal, Galapagos Now Working with Gilead

6.3 BTK Inhibitors

6.3.1 BMS-986142: Well Tolerated in Phase 1

6.3.2 HM71224: Collaboration with Eli Lilly

6.4 GM-CSF Inhibitor

6.4.1 GSK 3196165: Potential Role in Early Disease

7. Leading Companies in the Rheumatoid Arthritis Drugs Market, 2016

7.1 Introduction to the Leading Companies

7.2 AbbVie: Secured Multiple Patents for Humira

7.3 Roche: Second-Leading Company

7.4 Johnson & Johnson: High Hopes for Sirukumab

7.5 Amgen: Enbrel Sales Protected in the US

7.6 Pfizer: Actively Developing Biosimilars

7.7 Merck & Co.: Remicade Sales in Decline

7.8 BMS: Exploring Additional Indications for Orencia

7.9 UCB: Reliant on Cimzia Revenue

8. Qualitative Analysis of the Rheumatoid Arthritis Drugs Market 2017-2027

8.1 Strengths and Weaknesses of the Rheumatoid Arthritis Market, 2017

8.1.1 Number of Elderly Patients Expected to Rise

8.1.2 Biologics Already Recognised as a Valuable Part of Treatment

8.1.3 Biologics Used in RA Often Have Multiple Indications

8.1.4 Some Patients Have an Inadequate Treatment Response

8.1.5 Efficacy of Drugs Can Diminish Over Time

8.2 Opportunities and Threats Facing the Rheumatoid Arthritis Market, 2017-2027

8.2.1 Need for Effective Drugs With Better Safety Profiles

8.2.2 Need for Less Invasive Routes of Administration

8.2.3 High Number of Products Will Saturate Market

8.2.4 Competition from Biosimilars Will Increase

8.3 Social, Technological, Economic and Political Factors Affecting the Rheumatoid Arthritis Market (STEP Analysis), 2017-2027

8.3.1 Social Factors Influencing the Rheumatoid Arthritis Market

8.3.2 Technological Factors Influencing the Rheumatoid Arthritis Market

8.3.3 Economic Factors Influencing the Rheumatoid Arthritis Market

8.3.4 Political Factors Influencing the Rheumatoid Arthritis Market

8.3.4.1 Government Pressure to Control Costs

8.3.4.2 Inter-country Variability in Biosimilar Approval Process

9. Conclusions

9.1 Global Market for RA Drugs Will Contract After 2018

9.2 Biologics Will Remain the Dominant Drug Class but their Market Share Will Drop By 10%

9.3 Enbrel Will Overtake Humira as the Leading Drug

9.4 US Will Remain the Dominant Market

9.5 Trends in the RA Drugs Market

Some Associated Reports

Visiongain Report Sales Order Form

Appendix A

About Visiongain

Appendix B

Visiongain Report Evaluation Form

List of Figures

Figure 1.1 Main Segments and Sub-Segments of the Rheumatoid Arthritis Market, 2016

Figure 3.1 The Total RA Drugs Market: Market Share (%) by Indication, 2016

Figure 3.2 The RA Drugs Market: Market Share (%) by Submarket, 2016

Figure 3.3 The Drugs Market for RA: Revenue ($m) Forecast, 2017-2027

Figure 3.4 The RA Drugs Market Segments: Revenue* ($m) Forecast, 2016-2027

Figure 3.5 The RA Drugs Market: Market Share (%) by Segment, 2021

Figure 3.6 The RA Drugs Market: Market Share (%) by Segment, 2027

Figure 3.7 Non-Biologics for RA: Revenue* ($m) Forecasts by Segment, 2016-2027

Figure 3.8 Non-Biologics for RA: Market Share (%), 2016

Figure 3.9 Non-Biologics for RA: Market Share (%), 2021

Figure 3.10 Non-Biologics for RA: Market Share (%), 2027

Figure 3.11 NSAIDs: Revenue ($m) Forecast, 2016-2027

Figure 3.12 sDMARDs: Revenue ($m) Forecast, 2016-2027

Figure 3.13 Others: Revenue ($m) Forecast, 2016-2027

Figure 3.14 Biologics for RA: Revenue ($m) Forecast, 2016-2027

Figure 4.1 The Main Drugs in the RA Market: Market Shares (%), 2016.

Figure 4.2 Humira: Revenue ($m) Forecast, 2016-2027

Figure 4.3 Enbrel: Revenue ($m) Forecast, 2016-2027

Figure 4.4 Remicade: Revenue ($m) Forecast, 2016-2027

Figure 4.5 Rituxan: Revenue ($m) Forecast, 2016-2027

Figure 4.6 Simponi: Revenue ($m) Forecast, 2016-2027

Figure 4.7 Orencia: Revenue ($m) Forecast, 2016-2027

Figure 4.8 Actemra: Revenue ($m) Forecast, 2016-2027

Figure 4.9 Cimzia: Revenue ($m) Forecast, 2016-2027

Figure 4.10 Celebrex: Revenue ($m) Forecast, 2016-2027

Figure 4.11 Xeljanz: Revenue ($m) Forecast, 2016-2027

Figure 4.12 Arcoxia: Revenue ($m) Forecast, 2016-2027

Figure 5.1 RA: Market Share (%) by Country, 2016

Figure 5.2 RA: Market Share (%) by Country, 2027

Figure 5.3 The US RA Drug Market: World Market Share (%), 2016

Figure 5.4 The US RA Drug Market: Revenue ($m) Forecast, 2016-2027

Figure 5.5 The RA Drug Market in Japan: World Market Share (%), 2016

Figure 5.6 The RA Drug Market in Japan: Revenue ($m) Forecast, 2016-2027

Figure 5.7 The EU5 RA Drug Markets: World Market Share (%), 2016

Figure 5.8 The EU5 RA Drug Markets: Revenue ($m) Forecast 2016-2027

Figure 5.9 The RA Drug Market in Germany: World Market Share (%), 2016

Figure 5.10 The RA Drug Market in Germany: Revenue ($m) Forecast 2016-2027

Figure 5.11 The RA Drug Market in France: World Market Share (%), 2016

Figure 5.12 The RA Drug Market in France: Revenue ($m) Forecast, 2016-2027

Figure 5.13 The RA Drug Market in Italy: World Market Share (%), 2016

Figure 5.14 The RA Drug Market in Italy: Revenue ($m) Forecast, 2016-2027

Figure 5.15 The RA Drug Market in Spain: World Market Share (%), 2016

Figure 5.16 The RA Drug Market in Spain: Revenue ($m) Forecast, 2016-2027

Figure 5.17 The RA Drug Market in the UK: World Market Share (%), 2016

Figure 5.18 The RA Drug Market in the UK: Revenue ($m) Forecast, 2016-2027

Figure 5.19 The RA Drug Market in China: World Market Share (%), 2016

Figure 5.20 The RA Drug Market in China: Revenue ($m) Forecast, 2016-2027

Figure 5.21 The RA Drug Market in India: World Market Share (%), 2016

Figure 5.22 The RA Drug Market in India: Revenue ($m) Forecast, 2016-2027

Figure 5.23 The RA Drug Market in Russia: World Market Share (%), 2016

Figure 5.24 The RA Drug Market in Russia: Revenue ($m) Forecast, 2016-2027

Figure 5.25 The RA Drug Market in Brazil: World Market Share (%), 2016

Figure 5.26 The RA Drug Market in Brazil: Revenue ($m) Forecast, 2016-2027

Figure 7.1 Leading Companies in the RA Drug Market: Market Share (%), 2016

Figure 7.2 AbbVie: Breakdown of Revenue (%) by RA Drug, 2016

Figure 7.3 Roche: Breakdown of Revenue (%) by RA Drug, 2016

Figure 7.4 J&J: Breakdown of Revenue (%) by RA Drug, 2016

Figure 7.5 Amgen: Breakdown of Revenue (%) by RA Drug, 2016

Figure 7.6 Pfizer: Breakdown of Revenue (%) by RA Drug, 2016

Figure 7.7 Merck & Co: Breakdown of Revenue (%) by RA Drug, 2016

Figure 7.8 BMS: Breakdown of Revenue (%) by RA Drug, 2016

Figure 7.9 UCB: Breakdown of Revenue (%) by RA Drug, 2016

Figure 9.1 RA Drugs Market: Comparison of Revenue ($m) Forecasts for Total Market* and Market for RA Indication^, 2016-2027

Figure 9.2 RA Drugs Market: Comparison of Revenue* ($m) Forecasts for Biologic and Non-Biologic Segments, 2016-2027

Figure 9.3 The Leading Drugs in the RA Market: Revenue* ($m) Forecasts, 2016, 2022, 2027

Figure 9.4 The Leading National Markets for RA Drugs: Revenue* ($m) Forecasts, 2016, 2022, 2027

List of Tables

Table 1.1 Sample

Table 2.1 Biologic Agents and Mechanism of Action

Table 2.2 Comorbidities Associated with RA in Different Organs

Table 2.3 Prevalence rate of RA in Different Countries

Table 3.1 The RA Drugs Market by Submarket, 2016

Table 3.2 The Drugs Market for RA: Revenue* ($m) Forecast, 2016-2027

Table 3.3 The RA Drugs Market Segments Forecast: Revenue* ($m), AGR (%) & CAGR (%) 2016-2027

Table 3.4 Non-Biologics for RA: Revenue* ($m) Forecasts by Segment, 2016-2027

Table 3.5 NSAIDs for RA Forecasts: Revenue* ($m), AGR (%) and CAGR (%), 2016-2027

Table 3.6 sDMARDs for RA Forecasts: Revenue* ($m), AGR (%) and CAGR (%), 2016-2027

Table 3.7 Other Drugs for RA Forecasts: Revenue* ($m), AGR (%) and CAGR (%), 2016-2027

Table 3.8 Biologics for RA Forecasts: Revenue* ($m), AGR (%) and CAGR (%), 2016-2027

Table 4.1 The Main Drugs in the RA Market: Revenue* ($m) and Market Share (%), 2016

Table 4.2 The Main Drugs in the RA Market Forecasts: Revenue* ($m), AGR (%) and CAGR (%), 2016-2027

Table 4.3 Humira: Key Facts

Table 4.4 Adalimumab Biosimilars: Current Status, 2016

Table 4.5 Humira Forecasts: Revenue* ($m), AGR (%) and CAGR (%), 2016-2027

Table 4.6 Humira: Revenue ($m) and Market Share (%) Forecast, 2016-2027

Table 4.7 Enbrel: Key Facts

Table 4.8 Etanercept Biosimilars : Current Status, 2016

Table 4.9 Enbrel: Revenue ($m) and Market Share (%) Forecast, 2016-2027

Table 4.10 Remicade: Key Facts

Table 4.11 Infliximab Biosimilars: Current Status, 2016

Table 4.12 Remicade: Revenue ($m) and Market Share (%) Forecast, 2016-2027

Table 4.13 Rituxan: Key Facts

Table 4.14 Rituximab Biosimilars: Current Status, 2016

Table 4.15 Rituxan: Revenue ($m) and Market Share (%) Forecast, 2016-2027

Table 4.16 Simponi: Key Facts

Table 4.17 Simponi: Revenue ($m) and Market Share (%) Forecast, 2016-2027

Table 4.18 Orencia: Key Facts

Table 4.19 Orencia: Revenue ($m) and Market Share (%) Forecast, 2016-2027

Table 4.20 Actemra: Key Facts

Table 4.21 Actemra: Revenue ($m) and Market Share (%) Forecast, 2016-2027

Table 4.22 Cimzia: Key Facts

Table 4.23 Cimzia: Revenue ($m) and Market Share (%) Forecast, 2016-2027

Table 4.24 Celebrex: Key Facts

Table 4.25 Celebrex: Revenue ($m) and Market Share (%) Forecast, 2016-2027

Table 4.26 Xeljanz: Key Facts

Table 4.27 Xeljanz: Revenue ($m) and Market Share (%) Forecast, 2016-2027

Table 4.28 Arcoxia: Key Facts

Table 4.29 Arcoxia: Revenue ($m) and Market Share (%) Forecast, 2016-2027

Table 5.1 The Leading National Markets for RA: Revenue* ($m) and Market Share (%), 2016

Table 5.2 RA Drugs: Market Share (%) by Country, 2016 and 2027

Table 5.3 RA Drugs: Revenue ($m) Forecast by Country, 2016-2027

Table 5.4 The US RA Drug Market: Revenue ($m) and Market Share (%) Forecast, 2016-2027

Table 5.5 The RA Drug Market in Japan: Revenue ($m) and Market Share (%) Forecast, 2016-2027

Table 5.6 The EU5 RA Drug Markets: Revenue ($m) Forecast, 2016-2027

Table 5.7 The RA Drug Market in Germany: Revenue ($m) and Market Share (%) Forecast, 2016-2027

Table 5.8 The RA Drug Market in France: Revenue ($m) and Market Share (%) Forecast, 2016-2027

Table 5.9 The RA Drug Market in Italy: Revenue ($m) and Market Share (%) Forecast, 2016-2027

Table 5.10 The RA Drug Market in Spain: Revenue ($m) and Market Share (%) Forecast, 2016-2027

Table 5.11 The RA Drug Market in the UK: Revenue ($m) and Market Share (%) Forecast, 2016-2027

Table 5.12 The RA Drug Market in China: Revenue ($m) and Market Share (%) Forecast, 2016-2027

Table 5.13 The RA Drug Market in India: Revenue ($m) and Market Share (%) Forecast, 2016-2027

Table 5.14 The RA Drug Market in Russia: Revenue ($m) and Market Share (%) Forecast, 2016-2027

Table 5.15 The RA Drug Market in Brazil: Revenue ($m) and Market Share (%) Forecast, 2016-2027

Table 6.1 Pipeline R&D Products, 2016

Table 7.1 Leading Companies in the RA Drug Market: Revenue ($m) and Market Share (%), 2016

Table 7.2 AbbVie: Breakdown of Revenue ($m,%) by RA Drug, 2016

Table 7.3 Roche: Breakdown of Revenue ($m,%) by RA Drug, 2016

Table 7.4 J&J: Breakdown of Revenue ($m,%) by RA Drug, 2016

Table 7.5 Amgen: Breakdown of Revenue ($m,%) by RA Drug, 2016

Table 7.6 Pfizer: Breakdown of Revenue ($m,%) by RA Drug, 2016

Table 7.7 Merck & Co: Breakdown of Revenue ($m,%) by RA Drug, 2016

Table 7.8 BMS: Breakdown of Revenue ($m,%) by RA Drug, 2016

Table 7.9 UCB: Breakdown of Revenue ($m,%) by RA Drug, 2016

Table 8.1 Strengths and Weaknesses of the Rheumatoid Arthritis Market, 2017

Table 8.2 Opportunities and Threats Facing the Rheumatoid Arthritis Market, 2017-2027

Table 8.3 Social, Technological, Economic and Political Factors Influencing the RA Market, 2016-2026

Table 9.1 Drivers and Restraints of the RA Drugs Market, 2017-2027